Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 8/20 | 0.44 |
| ▸ | ACACA | Q13085 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384061 | 0.80 | GPR119 (0.63) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2383853 | 0.79 | LDHA (0.44) | F10ALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL2385162 | 0.78 | CKS1B (0.49) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL803332 | 0.78 | CKS1B (0.56) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL2384241 | 0.77 | ALDH1A1 (0.54) | F10ALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL12251225 | 0.77 | ALDH1A1 (0.53) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2385264 | 0.77 | GPR119 (0.59) | CKS1BSKP1SKP2ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL2384760 | 0.76 | ALDH1A1 (0.52) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL14019295 | 0.76 | DRD2 (0.51) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL5366155 | 0.75 | ALDH1A1 (0.52) | CKS1BSKP1SKP2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | CKS1B 192/4885SKP1 918/4885SKP2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.